Tesofensine

Tesofensine
Clinical data
Pregnancy; category	Not applicable;
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Pharmacokinetic data
Bioavailability	90%
Metabolism	15–20% renal; hepatic: CYP3A4
Elimination half-life	220 hours
Excretion	Not applicable
Identifiers
	IUPAC name (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane;
CAS Number	195875-84-4 ;
PubChem CID	11370864;
ChemSpider	9545781 ;
UNII	BLH9UKX9V1;
CompTox Dashboard (EPA)	DTXSID70905114 ;
Chemical and physical data
Formula	C17H23Cl2NO
Molar mass	328.28 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(cc1Cl)[C@H]3C[C@H]2N(C)[C@H](CC2)[C@@H]3COCC;
	InChI InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1 ; Key:VCVWXKKWDOJNIT-ZOMKSWQUSA-N ;
	(what is this?) (verify)

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.^[1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.^[2]

As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.^[3]

^ Cite error: The named reference Doggrell was invoked but never defined (see the help page).
^ "NeuroSearch A/S signs agreement to transfer Phase I-II projects NS2359 and NS2330 (Tesofensine)". NeuroSearch company announcement. Retrieved 30 October 2014.
^ "Tesofensine - Saniona". AdisInsight. Springer Publishing. 29 January 2019. Retrieved 31 October 2019.

[Doggrell-1] Cite error: The named reference Doggrell was invoked but never defined (see the help page).

[2] "NeuroSearch A/S signs agreement to transfer Phase I-II projects NS2359 and NS2330 (Tesofensine)". NeuroSearch company announcement. Retrieved 30 October 2014.

[3] "Tesofensine - Saniona". AdisInsight. Springer Publishing. 29 January 2019. Retrieved 31 October 2019.

[1]

[2]

[3]

Clinical data

Pregnancy category	Not applicable
Routes of administration	Oral
ATC code	None
Legal status
Legal status	US: Investigational New Drug
Pharmacokinetic data
Bioavailability	90%
Metabolism	15–20% renal; hepatic: CYP3A4
Elimination half-life	220 hours
Excretion	Not applicable
Identifiers
IUPAC name (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
CAS Number	195875-84-4^N
PubChem CID	11370864
ChemSpider	9545781^N
UNII	BLH9UKX9V1
CompTox Dashboard (EPA)	DTXSID70905114
Chemical and physical data
Formula	C₁₇H₂₃Cl₂NO
Molar mass	328.28 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1Cl)[C@H]3C[C@H]2N(C)[C@H](CC2)[C@@H]3COCC
InChI InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1^N Key:VCVWXKKWDOJNIT-ZOMKSWQUSA-N^N
^NY (what is this?) (verify)